<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-CH0T1W5O/17c44bf2-c0b4-4e27-9b70-6a745e982b3d/PDF"><dcterms:extent>2034 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-CH0T1W5O/62003a70-e8e5-4dd2-b250-c61fcf1c9268/TEXT"><dcterms:extent>40 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-CH0T1W5O"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2025</dcterms:issued><dc:creator>Krajšek, Zala</dc:creator><dc:creator>Rotman Primec, Jaka</dc:creator><dc:creator>Urbančič, Dunja</dc:creator><dc:format xml:lang="sl">številka:1</dc:format><dc:format xml:lang="sl">letnik:76</dc:format><dc:format xml:lang="sl">str. 39-48</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID_HOST:230988547</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-CH0T1W5O</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">celični modeli in vitro</dc:subject><dc:subject xml:lang="sl">inducirane pluripotentne matične celice</dc:subject><dc:subject xml:lang="sl">Matične celice</dc:subject><dc:subject xml:lang="sl">odkrivanje novih zdravilnih učinkovin</dc:subject><dc:subject xml:lang="sl">predklinične študije</dc:subject><dc:subject xml:lang="sl">Zdravilne učinkovine</dc:subject><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Inducirane pluripotentne matične celice pri odkrivanju in vrednotenju zdravilnih učinkovin| Induced pluripotent stem cells in drug discovery|</dc:title><dc:description xml:lang="sl">Induced pluripotent stem cells have become an important tool for drug discovery in recent years, offering significant advantages over traditional models, such as primary cells, cancer cell lines, and animal models. These cells are derived by reprogramming somatic cells into a pluripotent state, allowing differentiation into various cell types while retaining the genetic information of the individual. In drug discovery, models from induced pluripotent stem cells encompass twodimensional cultures, three-dimensional models, and more sophisticated organs-on-a-chip. These advanced models enable more accurate assessment of drug toxicity and efficacy, compound interactions, as well as detailed studies of disease mechanisms. however, challenges in application of induced pluripotent stem cells remain, including limited cellular maturity, variability across obtained cell lines, and high costs, which currently restrict their broader use in the pharmaceutical field. Despite these limitations, induced pluripotent stem cells hold great promise for the development of personalised therapies and the discovery of novel therapeutic approaches</dc:description><dc:description xml:lang="sl">Inducirane pluripotentne matične celice so v zadnjih letih postale pomembno orodje za odkrivanje zdravilnih učinkovin, saj ponujajo bistvene prednosti pred tradicionalnimi modeli, kot so primarne celice, rakave celične linije in živalski modeli. Pridobimo jih z reprogramiranjem somatskih celic v pluripotentno stanje, kar omogoča njihovo diferenciacijo v različne tipe celic ob ohranjanju dedne informacije posameznika. Pri uporabi induciranih pluripotentnih matičnih celic za odkrivanje zdravilnih učinkovin je na voljo več modelov, vključno z dvodimenzionalnimi kulturami, enostavnejšimi tridimenzionalnimi modeli in naprednejšimi modeli – organi na čipu. Tovrstni modeli omogočajo natančnejšo oceno toksičnosti in učinkovitosti zdravilnih učinkovin, njihovih medsebojnih interakcij ter proučevanje mehanizmov bolezni. Izzivi, s katerimi se soočamo ob uporabi induciranih pluripotentnih matičnih celic, so: njihova nezadostna zrelost, variabilnost med pridobljenimi celičnimi linijami in visoki stroški, kar trenutno omejuje njihovo širšo uporabo v farmaciji. Kljub tem omejitvam imajo inducirane pluripotentne matične celice velik potencial za razvoj personaliziranih oblik zdravljenja in odkrivanje novih terapevtskih pristopov</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-CH0T1W5O"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-CH0T1W5O" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-CH0T1W5O/17c44bf2-c0b4-4e27-9b70-6a745e982b3d/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-CH0T1W5O/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-CH0T1W5O" /></ore:Aggregation></rdf:RDF>